Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2011-10-10 Call Transcript
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Quarterly Investor Conference Call 1 page 25.6KB
Call Transcript Classification · 70% confidence The document is a media release announcing an upcoming investor teleconference to discuss the September 2011 Quarterly Report. It does not contain the actual quarterly financial data or substantive analysis but rather informs about the timing and access details for the conference call. The document length is short (1179 characters), and it explicitly states the report will be released the day before the call. Therefore, this is an announcement related to a conference call, not the call transcript itself or the quarterly report. Given the content, the best classification is Call Transcript (CT) because the document is about the conference call event, but since it is only an announcement and not the transcript, the closest fitting category is CT with moderate confidence. However, since it is only an announcement of the call and not the transcript, and no transcript text is included, the fallback is Regulatory Filings (RNS). But the document is specifically about a conference call event, so CT is more appropriate than RNS.
2011-10-10 English
Change in substantial holding 4 pages 58.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Notice of Change of Interest of Substantial Holder (Form 604) filed under section 671B(3) of the Corporations Act 2001 (Cth). It details changes in voting power and relevant interests of a substantial shareholder in Pharmaxis Ltd, including dates, share counts, and nature of changes. The document is regulatory in nature, reporting shareholding changes rather than financial results or management information. It is not an annual report, earnings release, or any form of financial statement. It fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2011-10-09 English
Phase II Trial in Allergic Asthma Completes Recruitment 2 pages 97.6KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 29 September 2011 from Pharmaxis Ltd announcing the completion of enrolment in a Phase II clinical trial for a new asthma treatment. It provides detailed information about the trial design, endpoints, and company background. There is no indication that this is a financial report, regulatory filing, or any form of corporate governance or shareholder communication. It is a clinical trial update, which does not fit into any of the specific financial or corporate filing categories. The closest relevant category for such announcements, which are not financial or regulatory filings, is Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit elsewhere.
2011-09-28 English
2011 Annual Report to Shareholders 96 pages 1.2MB
Annual Report Classification · 100% confidence The document is titled '2011 Statutory Annual Report' and includes detailed sections such as Directors' Report, Financial Statements, Remuneration Report, Corporate Governance, Senior Management, Operating and Financial Review, and Auditor's Report. It covers the full fiscal year ended 30 June 2011 and contains comprehensive financial data and management discussion. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content matches the characteristics of an official yearly report covering company activity and full financial performance, which corresponds to an Annual Report (10-K equivalent). FY 2011
2011-09-28 English
Update on EU Bronchitol Marketing Application 2 pages 98.5KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 28 September 2011 from Pharmaxis Ltd announcing the status update on the re-examination of the European Bronchitol marketing application by the Committee for Medicinal Products for Human Use (CHMP). It discusses regulatory progress, clinical trial results, and forward-looking statements about the product's potential approval and availability. The document is a public announcement about regulatory and marketing application progress rather than a detailed financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it is a standalone media release providing an update on regulatory status. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Capital Update.
2011-09-27 English
Change of Director`s Interest Notice 3 pages 81.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including shareholdings and options, as well as the director's appointment to a company holding shares. The document is a formal notification of a director's personal share transactions and interests, consistent with insider trading disclosures. It does not contain financial statements, management discussion, or other report content. The document length is 4148 characters, which is typical for such notices. Therefore, the correct classification is Director's Dealing (DIRS).
2011-09-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.